Gaudium IVF's 11th AGM Concludes: All Resolutions Approved by Shareholders
Gaudium IVF's 11th AGM on September 28, 2026, approved all resolutions. Key approvals include financial statements, director re-appointments, and remuneration adjustments for key management personnel. The company also appointed secretarial auditors for a five-year term.
The approval of financial statements, director re-appointments, and remuneration adjustments are routine but important corporate actions that impact governance and operational continuity. The appointment of secretarial auditors for a long term provides stability.
All resolutions presented at the AGM were approved by shareholders with the required majority, indicating positive shareholder engagement and approval of the company's proposed actions.
Gaudium IVF and Women Health Limited held its 11th Annual General Meeting (AGM) on Monday, September 28, 2026, concluding at 03:13 P.M. IST. The meeting, conducted via Video Conferencing / Other Audio Visual Means (VC/OAVM), saw all proposed resolutions approved by the shareholders with the requisite majority.
Key resolutions passed included the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Additionally, shareholders approved the re-appointment of Mr. Vishad Khanna as a Non-Executive Director, the revision in remuneration for Dr. Peeyush Khanna (Whole-Time Director), and the ratification of remuneration for Dr. Manika Khanna (Chairperson and Managing Director). The appointment of M/s. Suresh Nainwal & Company as Secretarial Auditors for a five-year term was also ratified.
The voting results, including remote e-voting and e-voting during the AGM, were consolidated and reported by Suresh Chandra Nainwal, Proprietor of M/s. Suresh Chandra Nainwal & Company. The company's website and the National Securities Depository Limited (NSDL) website also host this information.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.